Emerging Roles of Exosomes in Huntington’s Disease
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Huntington’s disease (HD) is a rare hereditary autosomal dominant neurodegenerative disorder, which is caused by expression of mutant huntingtin protein (mHTT) with an abnormal number of glutamine repeats in its N terminus, and characterized by intracellular mHTT aggregates (inclusions) in the brain. Exosomes are small extracellular vesicles that are secreted generally by all cell types and can be isolated from almost all body fluids such as blood, urine, saliva, and cerebrospinal fluid. Exosomes may participate in the spreading of toxic misfolded proteins across the central nervous system in neurodegenerative diseases. In HD, such propagation of mHTT was observed both in vitro and in vivo. On the other hand, exosomes might carry molecules with neuroprotective effects. In addition, due to their capability to cross blood-brain barrier, exosomes hold great potential as sources of biomarkers available from periphery or carriers of therapeutics into the central nervous system. In this review, we discuss the emerging roles of exosomes in HD pathogenesis, diagnosis, and therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Théry, C., Witwer, K. W., Aikawa, E., Alcaraz, M. J., Anderson, J. D., Andriantsitohaina, R., Antoniou, A., Arab, T., Archer, F., Atkin‐Smith, G. K., et al. (2018) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2018.1535750 · Cited by 11,099 · cited 1×
“, exosomes, microvesicles, and apoptotic bodies (Figure 1) [1,2].”
Shedding light on the cell biology of extracellular vesicles
van Niel, G., D'Angelo, G., & Raposo, G. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.125 · Cited by 8,369
Biological properties of extracellular vesicles and their physiological functions
Yáñez‐Mó, M., Siljander, P. R. ‐., Andreu, Z., Bedina Zavec, A., Borràs, F. E., Buzas, E. I., Buzas, K., Casal, E., Cappello, F., Carvalho, J., et al. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.27066 · Cited by 5,926 · cited 1×
“, exosomes, microvesicles, and apoptotic bodies (Figure 1) [1,2].”
Johnstone, R. M., Adam, M., Hammond, J. R., Orr, L., & Turbide, C. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)48095-7 · Cited by 2,931 · cited 1×
“Exosomes are nano sized EVs (40–120 nm) that were initially identified as a part of reticulocyte maturation in sheep [3].”
BackgroundExosomes: biogenesis, biologic function and clinical potential
Zhang, Y., Liu, Y., Liu, H., & Tang, W. H. (2019) · Cell & Bioscience · doi:10.1186/s13578-019-0282-2 · Cited by 2,119
Toxic Proteins in Neurodegenerative Disease
Taylor, J. P., Hardy, J., & Fischbeck, K. H. (2002) · Science · doi:10.1126/science.1067122 · Cited by 1,251
Fiandaca, M. S., Kapogiannis, D., Mapstone, M., Boxer, A., Eitan, E., Schwartz, J. B., Abner, E. L., Petersen, R. C., Federoff, H. J., Miller, B. L., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.06.008 · Cited by 959
Inactivation of the Mouse Huntington's Disease Gene Homolog Hdh
Duyao, M. P., Auerbach, A. B., Ryan, A., Persichetti, F., Barnes, G. T., McNeil, S. M., Ge, P., Vonsattel, J.-P., Gusella, J. F., Joyner, A. L., et al. (1995) · Science · doi:10.1126/science.7618107 · Cited by 723
Targeting Huntingtin Expression in Patients with Huntington’s Disease
Tabrizi, S. J., Leavitt, B. R., Landwehrmeyer, G. B., Wild, E. J., Saft, C., Barker, R. A., Blair, N. F., Craufurd, D., Priller, J., Rickards, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1900907 · Cited by 708 · cited 1×
“Antisense oligonucleotides Inhibit HTT mRNA and thereby reduce the concentration of mHTT, such as Tominersen (previously IONIS-HTTRx) * Intrathecal [51]”
BackgroundPacker, A. N., Xing, Y., Harper, S. Q., Jones, L., & Davidson, B. L. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2390-08.2008 · Cited by 679 · cited 1×
“Several studies reported a decrease of miR-124 expression in HD patients’ brains [142,143], STHdhQ111/HdhQ111 HD cell line, and R6/2 HD mouse [144].”
BackgroundPlasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease
Shi, M., Liu, C., Cook, T. J., Bullock, K. M., Zhao, Y., Ginghina, C., Li, Y., Aro, P., Dator, R., He, C., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1314-y · Cited by 676
Exosome-mediated delivery of hydrophobically modified siRNA for huntingtin mRNA silencing
Didiot, M.-C., Hall, L. M., Coles, A. H., Haraszti, R. A., Godinho, B. M., Chase, K., Sapp, E., Ly, S., Alterman, J. F., Hassler, M. R., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.126 · Cited by 483 · cited 6×
“A small interfering RNA (siRNA) binds a target mRNA, guiding mRNA cleavage through RNA-induced silencing complex (RISC) which can provide effective long-term gene silencing [53,54].”
BackgroundMethodInfluentialAntonucci, F., Turola, E., Riganti, L., Caleo, M., Gabrielli, M., Perrotta, C., Novellino, L., Clementi, E., Giussani, P., Viani, P., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2011.489 · Cited by 328
Wang, S., Cesca, F., Loers, G., Schweizer, M., Buck, F., Benfenati, F., Schachner, M., & Kleene, R. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.6476-10.2011 · Cited by 324
The Transport Mechanism of Extracellular Vesicles at the Blood-Brain Barrier
Matsumoto, J., Stewart, T., Banks, W. A., & Zhang, J. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612823666170913164738 · Cited by 267 · cited 1×
“EVs, due to their ability to cross blood-brain barrier [146] and biocompatibility, are promising therapeutic drug carriers into the CNS in NDs with few ongoing preclinical trials in AD and PD [147–149].”
BackgroundAn updated role of microRNA-124 in central nervous system disorders: a review
Sun, Y., Luo, Z.-M., Guo, X.-M., Su, D.-F., & Liu, X. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00193 · Cited by 223 · cited 1×
“miR-124 was selected in the majority of exosome-based miRNA delivery studies for ND treatment because it is highly and specifically expressed in all brain regions except for the pituitary gland, and at 100 times lower expression in other tissues, and has a regulatory role in CNS development and diseases [151].”
BackgroundTransfer of polyglutamine aggregates in neuronal cells occurs in tunneling nanotubes
Costanzo, M., Abounit, S., Marzo, L., Danckaert, A., Chamoun, Z., Roux, P., & Zurzolo, C. (2013) · Journal of Cell Science · doi:10.1242/jcs.126086 · Cited by 210
Mutant huntingtin is present in neuronal grafts in huntington disease patients
Cicchetti, F., Lacroix, S., Cisbani, G., Vallières, N., Saint‐Pierre, M., St‐Amour, I., Tolouei, R., Skepper, J. N., Hauser, R. A., Mantovani, D., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24174 · Cited by 193 · cited 1×
“Interestingly, the possibility of the mHTT spreading into genetically unrelated tissue was confirmed in vivo in 3 HD patients undergoing fetal striatal tissue transplantation, where mHTT aggregates were formed in the transplanted tissue [115].”
BackgroundEvers, M. M., Miniarikova, J., Juhas, S., Vallès, A., Bohuslavova, B., Juhasova, J., Skalnikova, H. K., Vodicka, P., Valekova, I., Brouwers, C., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.06.021 · Cited by 168
Exosome-Based Delivery of miR-124 in a Huntington’s Disease Model
Lee, S.-T., Im, W., Ban, J.-J., Lee, M., Jung, K.-H., Lee, S. K., Chu, K., & Kim, M. (2017) · Journal of Movement Disorders · doi:10.14802/jmd.16054 · Cited by 164
Circulating Exosomal miRNA as Diagnostic Biomarkers of Neurodegenerative Diseases
Wang, L., & Zhang, L. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00053 · Cited by 164
Prion-like transmission of neuronal huntingtin aggregates to phagocytic glia in the Drosophila brain
Pearce, M. M. P., Spartz, E. J., Hong, W., Luo, L., & Kopito, R. R. (2015) · Nature Communications · doi:10.1038/ncomms7768 · Cited by 159
Hydrophobically Modified siRNAs Silence Huntingtin mRNA in Primary Neurons and Mouse Brain
Alterman, J. F., Hall, L. M., Coles, A. H., Hassler, M. R., Didiot, M.-C., Chase, K., Abraham, J., Sottosanti, E., Johnson, E., Sapp, E., et al. (2015) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2015.38 · Cited by 158 · cited 3×
“RNA interference (RNAi) Targeting HTT mRNA using hydrophobically-modified siRNAs (hsiRNA) Direct uptake in cell culture [53]”
BackgroundMethodProteomic analysis of urinary extracellular vesicles reveal biomarkers for neurologic disease
Wang, S., Kojima, K., Mobley, J. A., & West, A. B. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.06.021 · Cited by 145 · cited 1×
“HD, which makes the urinary EVs a highly accessible resource for biomarker discovery with particular promise for NDs [135].”
BackgroundExosomes from adipose‐derived stem cells ameliorate phenotype of Huntington's disease in vitro model
Lee, M., Liu, T., Im, W., & Kim, M. (2016) · European Journal of Neuroscience · doi:10.1111/ejn.13275 · Cited by 141 · cited 6×
“Similarly, exosomes secreted from adipose-derived stem cells, that are known to release neurotrophic factors, were shown to reduce the mHTT aggregates, mitochondrial dysfunction, and cell apoptosis of in vitro HD model [118].”
BackgroundInfluentialPotential Contribution of Exosomes to the Prion-Like Propagation of Lesions in Alzheimer’s Disease
Vingtdeux, V., Sergeant, N., & Buée, L. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00229 · Cited by 116
Pfister, E. L., DiNardo, N., Mondo, E., Borel, F., Conroy, F., Fraser, C., Gernoux, G., Han, X., Hu, D., Johnson, E., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.199 · Cited by 95 · cited 1×
“Targeting exon 48 of the human HTT mRNA using artificial miRNA (miR-155) Adeno-associated virus serotype 9 (AAV9) (Striatal and cortical injection) [61]”
MethodThe regulation of exosome function in the CNS: implications for neurodegeneration
Properzi, F., Ferroni, E., Poleggi, A., & Vinci, R. (2015) · Swiss Medical Weekly · doi:10.4414/smw.2015.14204 · Cited by 62 · cited 3×
“They mainly consist of lipids, proteins, nucleic acids, specifically mRNAs and miRNAs, and small molecules [16,17].”
BackgroundPlatelet-derived extracellular vesicles in Huntington’s disease
Denis, H. L., Lamontagne-Proulx, J., St-Amour, I., Mason, S. L., Weiss, A., Chouinard, S., Barker, R. A., Boilard, E., & Cicchetti, F. (2018) · Journal of Neurology · doi:10.1007/s00415-018-9022-5 · Cited by 32
Cited by
Ananbeh, H., Novak, J., Juhas, S., Juhasova, J., Klempir, J., Doleckova, K., Rysankova, I., Turnovcova, K., Hanus, J., Hansikova, H., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105598 · Cited by 46
Self-citationSmall Extracellular Vesicles’ miRNAs: Biomarkers and Therapeutics for Neurodegenerative Diseases
Lim, W. Q., Michelle Luk, K. H., Lee, K. Y., Nurul, N., Loh, S. J., Yeow, Z. X., Wong, Q. X., Daniel Looi, Q. H., Chong, P. P., How, C. W., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041216 · Cited by 25
(2024) · aging and disease · doi:10.14336/ad.2023.0614 · Cited by 9
“Over the years, exosome association with pathogenic proteins with seeding capacities, such as amyloid precursor protein [54, 56], α-Syn [17, 22, 57– 59], mutant huntingtin [60, 61], and scrapie isoform of the prion protein [62, 63], has been cemented.”
Background
Metadata
- Authors
- Ananbeh, H., Vodicka, P., & Kupcova Skalnikova, H.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-04-15
- Volume
- 22
- Issue
- 8
- Pages
- 4085
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3153863100
- Cited by
- 82
- References
- 29
- FWCI
- 3.22
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.